{
    "Trade/Device Name(s)": [
        "Rapid Urine Fentanyl (FYL) Test Strip",
        "Rapid Urine Fentanyl (FYL) Test Dipcard"
    ],
    "Submitter Information": "Co-Innovation Biotech Co., Ltd.",
    "510(k) Number": "K241100",
    "Predicate Device Reference 510(k) Number(s)": [
        "K231904"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NGL"
    ],
    "Summary Letter Date": "April 22, 2024",
    "Summary Letter Received Date": "April 22, 2024",
    "Submission Date": "May 22, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl (FYL)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Competitive binding",
        "Lateral flow immunochromatographic assay"
    ],
    "Methodologies": [
        "Immunochromatographic assay"
    ],
    "Submission Type(s)": [
        "Strip",
        "Dipcard"
    ],
    "Document Summary": "FDA 510(k) summary for OTC Rapid Urine Fentanyl (FYL) Test Strip and Test Dipcard for qualitative detection of fentanyl in urine at 1 ng/mL cutoff.",
    "Indications for Use Summary": "Qualitative detection of fentanyl in human urine for in vitro diagnostic use; provides preliminary results and requires confirmatory GC/MS or LC/MS testing.",
    "fda_folder": "Toxicology"
}